Kornimate/medical-research-clean huggingface dataset:
evaluation of the efficacy and safety of wearable ecg (at-patch) in patients with hypertrophic cardiomyopathy requiring 48-hour holter monitoringevaluation of the efficacy and safety of wearable ecg (at-patch) in patients with hypertrophic cardiomyopathy requiring 48-hour holter monitoring

Conditions: Hypertrophic Cardiomyopathy

Summary: * validation of validity, superiority, and safety of data analysis results using at-patch compared to 48-hour holter test results * number of subjects: 100 (including 10% dropout rate) * performance and safety were verified by simultaneously attaching a 48-hour holter and a wearable holter device (atp-c75 or atp-c135).

prospective, sequential, superiority test patients diagnosed with hypertrophic cardiomyopathy who require 48-hour holter monitoring. * 48-hour holter vs atp-c75 (48-hour comparison/total time comparison) * 48-hour holter vs atp-c135 (48-hour comparison/total time comparison) * comparison between ids

Eligibility criteria:
inclusion criteria: 1. male and female subjects aged 19 years or older 2. subjects diagnosed with hypertrophic cardiomyopathy who require 48-hour holter examination exclusion criteria: 1. those judged by the investigator to be unsuitable for this clinical trial or those who may increase the risk due to participation in the clinical trial 2. those with sensitive or allergic skin, skin diseases such as skin cancer or rashes 3. those with pacemakers, implantable cardioverter-defibrillators, or other implantable electrical devices 4. pregnant women
life with phenylketonuria. adult neurological outcome of pcu screened patients from 1971 to 2002.

Conditions: Phenylketonurias

Summary: you were detected during the neonatal period for phenylketonuria and you benefited from the diagnosis of an adapted dietetic care, and this for a variable duration according to the recommendations followed at that time. the recommendations for the management of phenylketonuria have evolved considerably over time, lengthening the duration, rigor of the diet and target rates. however, few studies have been able to determinate the influence of metabolic balance and pediatric management on fate in adulthood. as you know, the current recommendations are more stringent and prolonged, without taking into account the pediatric data of today's adult patients. the objective of this study, which is aimed at all adult patients screened and followed by lille university hospital, according to the same care methods, allowing a homogeneous monitoring of patients, is to assess the influence of pediatric care (duration of the diet, metabolic balance, compliance) on the future in adulthood. this retrospective and current analysis work could help refine the current recommendations.


Eligibility criteria:
inclusion criteria: * patients with classic or atypical phenylketonuria detected in the neonatal period since 1971 in the department of nord (59) and pas de calais (62). * patients treated * able to receive information * patient beneficiary or affiliated to a social security exclusion criteria: * patients not screened (born outside french territory) or before 1971. * untreated screened patients * patients screened for persistent benign hyperphenylalaninaemia not treated with a diet (phenylalanine level \<10 mg / dl or 600 µmol / l without diet to be confirmed) * associated confirmed neurological pathology other than a complication of phenylketonuria. * refusal to participate in the assessment of intellectual quotient in adulthood * patient screened, lost to follow-up, found, having moved to another region and not wishing to return to the chu for follow-up. * inability to receive information and or express opposition * opposition to participation in the study

Keywords: becoming neurological in adulthood metabolic balance during childhood duration and compliance with the low-protein diet
using a mouthwash containing propolis, clove oil and chlorhexidine to improve the caries risk of high risk patients

Conditions: Caries, Dental; Risk Reduction

Summary: this study is conducted to determine if using a mouthwash containing propolis, clove oil and chlorhexidine will improve the caries risk of high risk patients in comparison to using a mouthwash containing chlorhexidine only.

a total of 64 patients will be assigned in this study. patients will be randomly divided into two groups according to type of mouthwash (a) where group a1 patients will use chlorhexidine mouthwash as control group while group a2 patients will use chlorhexidine with propolis and clove oil mouthwash as intervention group with 32 patients in each group. each group will be further divided into two groups according to times of application (t) where t1 represents patients using the mouthwash once daily for one week every month for 6 months and t2 where patients will use the mouthwash twice daily for one week every month for 6 months with 16 patients in each subgroup.

Eligibility criteria:
inclusion criteria: * patients should be over 18 years of age. * patients should be with high caries risk assessment. exclusion criteria: * patients with a compromised medical history. * severe or active periodontal disease. * patients with a diseased salivary gland * history of allergies or other adverse reactions to chlorhexidine, propolis, bee stings, or clove * patients on any antibiotics during the past month

Keywords: dental caries propolis chlorhexidine clove oil bee wax
heart rate reduction in heart failure

Conditions: Heart Failure

Summary: patients with heart failure (hf) have a limited exercise tolerance,few pharmacological interventions have been proven effective in improving exercise capacity. at the presence there i conflicting evidence on the effectiveness of beta-blockers on exercise capacity. ivabradine has been shown to improve prognosis in patients with ischemic heart disease, left ventricular dysfunction and heart rate \> 70 bpm. the association of ivabradine and atenolol has been proven effective in increasing exercise tolerance in patients with ischemic heart disease. aim of the present study is to evaluate the effect of heart rate reduction with ivabradine, carvedilol or their combination in patients with heart failure of ischemic origin.

patients with chronic heart failure of ischemic origin (120) stable coronary artery disease acute coronary syndromes \> 3 months revascularization procedures \> 3 months naive on heart rate reducing agents new york heart association (nyha) class ii iii 6 minute walking test (6mw) tolerance between 200 and 400 m stable medications for the past 3 months treatment ivabradine up to 7.5 mg b.i.d. carvedilol up to 25 mg b.i.d. carvedilol and ivabradine up to 12.5/5 mg b.i.d. efficacy measure intention to treat exercise tolerance quality of life

Eligibility criteria:
inclusion criteria: * heart failure ii-iii * ischemic origin * stable medications from at least 3 months * \> 3 months from an acute ischemic syndrome or revascularization procedure * naive on heart rate reducing agents exclusion criteria: * bradycardia * hypersensitivity or contraindications to study drugs * exercise tolerance at 6 minute walking test \ 400 m

Keywords: heart failure heart rate ivabradine carvedilol
training programs to improve outcomes for individuals with spinal cord injury

Conditions: Spinal Cord Injuries

Summary: the objective of this study is to determine the effectiveness of different training programs on outcomes in persons with spinal cord injury (sci). we are interested to see which programs have the greatest impact.


Eligibility criteria:
inclusion criteria: * 18 to 75 years old * use either a power or manual wheelchair as a primary means of mobility (\>50% of weekly mobility) * living in the community * must have a non-progressive spinal cord injury * manual wheelchair users must be able to independently propel their wheelchairs * manual wheelchair users score ≤90 on the wheelchair skills training questionnaire (wst-q) exclusion criteria: * cognitive impairment that could interfere with learning

Keywords: quality of life participation training
intra versus extra-thoracic oscillations in chronic obstructive pulmonary disease

Conditions: Chronic Obstructive Pulmonary Disease

Summary: chronic obstructive pulmonary disease (copd) is the fourth-leading cause of death. it is a progressive illness that requires life-long treatment.promoting airway clearance (ac) using mucolytics together with airway clearance techniques (acts) form the basis for pulmonary therapy in copd care.therefore, new airway clearance modalities are required to decrease the detrimental effects of accumulated secretions in copd. one of the devices used in ac is the high frequency chest wall oscillation (the vest). hfcwo involves the use of an inflatable vest/jacket that covers the chest and is attached to an air pulse-generating compressor which rapidly inflates and deflates the vest, producing oscillations to the chest wall of 5-25 hz. another new airway clearance modality is oscillating positive expiratory pressure(quake) which combines pep therapy with high frequency oscillations.

the present study aimed to evaluate the effectiveness of the extra thoracic oscillations via high frequency chest wall oscillation vest (hfcwo) versus the intra thoracic oscillations via oscillatory positive expiratory pressure (opep) quake device in copd group a: consists of 30 patients will be treated by high frequency chest wall oscillation vest along with their prescribed medical treatment. this program will be performed 4 times per week for 6 successive weeks. group b: consists of 30 patients will be treated by vibratory pep (the quake) along with their prescribed medical treatment. this program will be performed 4 times per week for 6 successive weeks.

Eligibility criteria:
inclusion criteria: * • all patients were diagnosed by chest physician based on the modified criteria defined in the global initiative for chronic obstructive lung disease (gold) guidelines 2017. * all patients were diagnosed as copd for at least two years. * all patients must use their prescribed medications. exclusion criteria: * all patients that had one of the following were excluded from the study. history of osteoporosis, significant gastro-esophageal reflux, hiatus hernia. recent acute cardiac event (6 weeks) or congestive cardiac failure. any significant musculoskeletal disorders. presence of active hemoptysis presence of malignant disease
ro7790121 for the treatment of moderate to severe active crohn's disease

Conditions: Crohns Disease

Summary: this phase 2, randomized, double-blind, multicenter, induction and maintenance study is designed to evaluate the safety and efficacy of ro7790121 (rvt-3101) in adult participants with moderate to severe active crohn's disease.


Eligibility criteria:
inclusion criteria: * moderately to severely active cd as defined by cdai and ses-cd, assessed by central read * elevated very soft or liquid stool frequency and/or abdominal pain * must have no response, insufficient response, loss of response and/or intolerance to at least 1 conventional therapy (e.g. corticosteroids) or advanced therapy exclusion criteria: * diagnosis of ulcerative colitis, indeterminate colitis, microscopic colitis, ischemic colitis, infectious colitis, radiation colitis or active diverticular disease * short gut syndrome * presence of an ostomy or ileoanal pouch * bowel resection or diversion with \~6-months

Keywords: crohns disease
va home-based emotional learning with practical skills

Conditions: Anxiety; Depression

Summary: the purpose of this study is to determine the feasibility and acceptability of providing evidence-based, person-centered, culturally tailored treatment for anxiety and/or depression via telephone to rural veterans receiving home-based primary care.

va-helps will include flexibility in both content and delivery to meet the needs of home based primary care (hbpc) veterans. content will be modular to meet the needs of both anxious and depressed participants. modular skills-based treatment has been used successfully with a range of clinical problems (chorpita et al., 2004; henin et al., 2001; wetherell et al., 2009, 2011), including our own group's work treating generalized anxiety disorder (gad) in primary care (calleo et al., in press) and anxiety-depression in patients with chronic illness (cully et al., 2010). to further support a patient-centered treatment approach, patients will have the opportunity to include r/s. research points to the importance of r/s in coping with illness, with 50-90% of patients reporting using their belief systems to enhance coping skills (koenig \& adams, 2008). along with content modifications, delivery of treatment should complement the needs of hbpc veterans. providing one initial in-home session, followed by telephone contact for subsequent sessions, allows cost effectiveness to be taken into consideration; and greater numbers of rural hbpc patients will have access to the intervention. treatment will involve approximately 6 to 8 weekly sessions lasting approximately 30-40 minutes each. after the first in-person session, all sessions will be delivered via telephone. at least one booster call (15-20 minutes) will occur during the month following completion of active treatment. all participants will complete assessments at baseline, 8 weeks, and 12 weeks.

Eligibility criteria:
inclusion criteria: * age 18 or older * part of home-based primary care * reside in a rural community, as defined by the us census bureau * symptoms of anxiety and/or depression exclusion criteria: * significant cognitive impairment * active suicidal intent * current uncontrolled psychosis, bipolar, or substance-abuse disorders within the past month

Keywords: anxiety depression geriatric veteran
phase 2/3 study evaluating the safety and efficacy of ptx-022 in treatment of adults with pachyonychia congenita

Conditions: Pachyonychia Congenita

Summary: this study evaluates the safety and efficacy of ptx-022, topical rapamycin, in the treatment of adults with moderate to severe pachyonychia congenita. this study includes four-parts, and if a participant completes all parts, the participant will have received at least 3-months of ptx-022 treatment.


Eligibility criteria:
inclusion criteria: * adult patients, 18 years or older * diagnosed pachyonychia congenita (pc), genetically confirmed * moderate to severe pc * able and willing to comply with all protocol-required activities * willing and able to provide written informed consent exclusion criteria: * any significant concurrent condition (including involving the inferior to the ankle) that could adversely affect participation. * any intentional changes in the patient's daily activities (associated with standing, walking and keeping balance), not resulting from an improvement in the patient's condition due to treatment. * patient's deemed by the investigator as unwilling or unable to remain compliant with all tests and procedures, including adherence to study drug administration and other protocol-required activities.

Keywords: pc
study of pomalidomide combination with rituximab and anti-pd-1 antibody （ppr） in third or later line therapy of dlbcl

Conditions: Diffuse Large B-cell Lymphoma (DLBCL)

Summary: this study aims to observe and explore the efficacy and safety of pomalidomide combination with rituximab and anti-pd-1 antibody in third or later line therapy of diffuse large b-cell lymphoma (dlbcl)


Eligibility criteria:
inclusion criteria: * patients voluntarily joined the study, signed the informed consent, and had good compliance; * patients with 18 years to 80 years(at the time of signing the informed consent); eastern cooperative oncology group performance status (ecog-ps) score: 0-2; * patients with histopathologically confirmed diffuse large b-cell lymphoma with evaluable lesions who did not achieve cr or relapsed after second-line therapy * female patients of reproductive age should agree that birth control (such as intrauterine device, birth control pills, or condoms) must be used during the study period and for six months after completion; having a negative serum pregnancy test within 7 days prior to study enrollment, and must be non-lactating; male patients should agree to use contraception during the study period and for six months after the end of the study. exclusion criteria: * pathological subtypes: primary central nervous system dlbcl or primary mediastinal large b-cell lymphoma. * presence of severe or uncontrolled comorbid conditions including, but not limited to, symptomatic congestive heart failure, uncontrolled hypertension, unstable angina, active peptic ulcer disease, or severe hemorrhagic disorders such as hemophilia a, hemophilia b, von willebrand disease, or history of spontaneous bleeding requiring transfusion or other medical interventions. * a history of any active immune or autoimmune disease, or a known history of allogeneic organ transplantation or allogeneic hematopoietic stem cell transplantation; * any active infection requiring systemic antimicrobial therapy within 14 days before starting study treatment, including, but not limited to, bacterial, fungal, and viral infections. * current participation in other clinical studies, or initiation of study drugs administration less than 4 weeks after completion of previous clinical study treatment. * patients with concomitant diseases that, in the investigator's judgment, may seriously endanger patients' safety or may interfere with the completion of the study, or are deemed unsuitable for inclusion for other reasons.
correlation of stn-dbs induced visuospatial changes and freezing of gait

Conditions: Parkinson Disease; Gait Disorders, Neurologic; Visuospatial/Perceptual Abilities

Summary: the purpose of this research is to determine how deep brain stimulation (dbs) for parkinson's disease affects attention and visuospatial function. additionally, this study will evaluate how deficits in visual attention are associated with freezing of gait (fog) in parkinson's disease. there is currently no reliable treatment for fog and little is understood about the underlying reason this occurs. some recent research has found that stimulating the right side of the brain seems to improve fog. the right side of the brain is also paramount for visual attention, which is why investigators are conducting this study.

fog is a common and frequently disabling symptom of pd, affecting more than half of all pwpd. it remains a complex and incompletely understood phenomenon, with no currently approved therapies. fog is often exacerbated during dual-tasks where attention is divided to multiple tasks. a well known method of provoking fog by pwpd and neurologists alike is to walk through doorways or through a crowded space, regions where spatial attention is necessary. similarly, significant visuospatial attention deficits have been found in pwpd who freeze compared to those do not. further evidence demonstrates that the stn is part of the circuit which modulates spatial attention, and that stn-dbs has a significant impact on visuospatial attention and is notably improved with right sided stimulation. indeed, visuospatial attention is largely considered to be predominantly lateralized to the right hemisphere. interestingly, one study showed that right stn-dbs stimulation affecting a volume of activated tissue (vat) connected to the right sensorimotor cortex showed a significant association with reduction in fog. the impact of stn-dbs on visuospatial attention and the degree to which this change in attention is associated with changes in fog has not yet been studied, and may well explain part of the pathophysiology of fog and how to treat pwpd who freeze. the present study will build on the aforementioned research by prospectively evaluating the impact of lateralized stn-dbs stimulation on visuospatial attention in pwpd, and correlating this with change in fog.

Eligibility criteria:
inclusion criteria: * subjects above 18 years of age * subjects with freezing of gait * subjects with bilateral stn-dbs surgery as part of their clinical care for parkinson's disease exclusion criteria: * uncorrected visual or hearing impairments, as indicated by self-report * individuals who are pregnant or expect to become pregnant during the course of the study * individuals with dementia or relevant brain lesions impacting cognition or gait

Keywords: freezing of gait subthalamic nucleus visuospatial attention deep brain stimulation
effect of fruit and vegetable consumption on immune function in the elderly

Conditions: Immune Function

Summary: the immune system undergoes a range of changes as individuals become elderly. these may manifest as an increasing susceptibility to infection or a tendency to develop autoimmune or malignant disease. multiple underlying factors contribute to this phenomenon of immunological aging, and in this study the investigators will examine the possibility that inadequate diet may be one such contributing factor. fruit and vegetable intake, which can be low in the elderly, is associated with reduced chronic disease risk. this proposal will test the hypothesis that increased fruit and vegetable intake may positively affect clinically relevant measures of immune function. one hundred healthy volunteers aged 65-85 years following a low fruit and vegetable diet (\<=2 portions/d) will be recruited and randomised to continue following their normal diet, or to consume at least 5 portions of fruit and vegetables daily for 16 weeks. immune function and biochemical markers of nutritional status will be assessed before and after the intervention period.


Eligibility criteria:
inclusion criteria: * age 65-85 years * habitual consumption of fruit and vegetables \<= 2 portions daily exclusion criteria: * those on special diets, taking nutritional supplements or medications known to affect immune function or absorption of nutrients * excessive alcohol consumption (\>28 u/week men or \>21 u/week women) * bmi\>35 kg/m2 * history of diabetes or dementia * pneumovax ii vaccination within previous 2 years * inability to provide informed consent * any other problem which would prevent adherence to a high fruit and vegetable diet * recent infection (\<3 weeks since completion of any antibiotic course or symptoms of viral illness)

Keywords: natural killer cell cytotoxicity antibody response tetanus toxoid vaccination pneumovax ii vaccination total serum immunoglobulins igg subclasses